AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02674672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaTech® (VenaTech Retrievable Filter)
Study NCT01623141 — intervention group
Intervention type: PROCEDURE
Intervention: Pressure Pain measurement
Description: The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
Study NCT00084812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00084812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safingol
Study NCT01142284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol, Probucol
Description: Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID
Study NCT01142284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol, Probucol
Description: Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID
Study NCT03508518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
Study NCT01065259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS MPH
Description: The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
Study NCT01065259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
Study NCT05223244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine, triamcinolone, and heparin (BTH)
Description: 30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
Study NCT05223244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl sulfoxide (DMSO)
Description: 50mL of DMSO and 1mL of triamcinolone (10mg/mL)
Study NCT02126917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER + 40% Alcohol
Description: HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
Study NCT02126917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER + 20% Alcohol
Description: HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
Study NCT02126917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER + 0% Alcohol
Description: HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
Study NCT02655588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Media-Based Problems Solving Treatment
Study NCT05447975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded.
Study NCT00637936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Inspiratory fraction during anaesthesia
Study NCT01295697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-2208
Description: Experimental
Study NCT02748317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
Study NCT00676936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
Study NCT00676936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Custom made capsules, Lactose, administered twice daily, intervention period 7 days
Study NCT02335112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
Study NCT02335112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT04643223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio tape with tension
Description: The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
Study NCT04643223 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: kinesio tape without tension
Description: The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
Study NCT01551134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fundoplication
Description: Primary fundoplication
Study NCT01551134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fundoplication
Description: Primary fundoplication
Study NCT01690689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant surgery
Description: surgery
Study NCT03113448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075% Capsaicin Lotion
Description: To apply 3-4 times per day, every day until 8 weeks then stop
Study NCT03113448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.075% Capsaicin Lotion
Description: To apply 3-4 times per day, every day until 8 weeks then stop
Study NCT03113448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: To apply 3-4 times per day, every day until 8 weeks then stop
Study NCT03113448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: To apply 3-4 times per day, every day until 8 weeks then stop
Study NCT03613116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
Study NCT03613116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
Study NCT00906113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of melphalan
Description: Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
Study NCT00906113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of melphalan into the ophthalmic artery
Description: Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
Study NCT01949948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: 0.4 mg/kg single bolus intravenously
Study NCT01949948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: 0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
Study NCT00054041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HspE7
Description: Given subcutaneously
Study NCT00054041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo large loop excision
Study NCT00054041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04212533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation
Study NCT04212533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rice starch tablets
Description: rice starch tablets as placebo
Study NCT02944942 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Patients undergoing general anesthesia
Study NCT02689245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Study NCT02689245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Study NCT02689245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Study NCT04294420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education program
Description: The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
Study NCT03597360 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
Study NCT03236142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIPS Operation
Description: The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
Study NCT03236142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Duodenal Switch Operation
Study NCT03754751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with the implementation of modified ERAS program
Description: Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Low-pressure pneumoperitoneum (8-9 mmHg)~2. Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~3. PONV prophylaxis in patients of risk~Postoperative care~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery
Study NCT03754751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy with standard perioperative treatment
Description: Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Standard CO2 pressure (12-14 mmHg)~2. No additional anesthesia~Postoperative care~1. Mobilization in 4-6 h after surgery~2. Fluid intake in 6 hours~3. Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery
Study NCT02872363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention A - Behavioural Regulation
Description: SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'
Study NCT02872363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention B - Priority
Description: SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'
Study NCT02733952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT02733952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericervical Tourniquet
Study NCT03898921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
Study NCT03898921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Description: RFA with a safe margin, RFA again if residual,no more than 3 times.
Study NCT04135196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voluntary forearm loading task
Description: voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
Study NCT00853918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $20 cash
Description: $20 cash incentive mailed with survey
Study NCT00853918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $50 cash
Description: $50 cash incentive mailed with survey
Study NCT00853918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $50 check
Description: $50 check incentive mailed with survey
Study NCT00853918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $100 check
Description: $100 check incentive mailed with survey
Study NCT02639091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-9343
Description: In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)
Study NCT02639091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
Study NCT02639091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
Study NCT01599104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
Study NCT01599104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg capsule one daily
Study NCT01599104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to LCZ696 or Olmesartan
Study NCT01599104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to LCZ696 or Olmesartan
Study NCT04479865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily
Study NCT02880020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02880020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02880020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04479865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily
Study NCT01179126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete multivessel revascularization
Description: After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
Study NCT01179126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stress echocardiography and revascularization if required
Description: after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
Study NCT03140995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Programme
Description: The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
Study NCT04479865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 150mg
Description: 1 patch once weekly
Study NCT02881164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index
Description: Subjects intake a low glycemic index breakfast
Study NCT02881164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic index
Description: Subjects intake a high glycemic index breakfast
Study NCT02379286 — intervention group
Intervention type: OTHER
Intervention: Investigation
Description: Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
Study NCT02003911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin suspension (200mg/5mL)
Study NCT02003911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04479865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 170mg
Description: 1 patch once weekly
Study NCT06224946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio
Description: the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
Study NCT02199340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iStep exercise test
Description: newly developed submaximal exercise test
Study NCT02199340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iStep exercise test
Description: newly developed submaximal exercise test
Study NCT02199340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPET exercise test
Description: maximal gold standard exercise test